JNJ 79635322
Alternative Names: JNJ-79635322Latest Information Update: 12 Jun 2025
At a glance
- Originator Janssen Research & Development
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Multiple myeloma
Most Recent Events
- 03 Jun 2025 Interim adverse events and efficacy data from a phase-I trial in Multiple myeloma released by Johnson & Johnson (NCT05652335)
- 15 Jan 2025 Phase-I clinical trials in Multiple myeloma (Combination therapy) in Israel, Australia (SC) (NCT06768489)
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Multiple Myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)